UroGen Net Income Per Share from 2010 to 2025

URGN Stock  USD 10.77  0.23  2.18%   
UroGen Pharma Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to drop to -4.28. During the period from 2010 to 2025, UroGen Pharma Net Loss quarterly data regression pattern had sample variance of  3.22 and median of (3.55). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(4.08)
Current Value
(4.28)
Quarterly Volatility
1.79338964
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check UroGen Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among UroGen Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 17.8 M or Selling General Administrative of 109.1 M, as well as many indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0 or Days Sales Outstanding of 98.77. UroGen financial statements analysis is a perfect complement when working with UroGen Pharma Valuation or Volatility modules.
  
Check out the analysis of UroGen Pharma Correlation against competitors.
To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

Latest UroGen Pharma's Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of UroGen Pharma over the last few years. It is UroGen Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in UroGen Pharma's overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

UroGen Net Income Per Share Regression Statistics

Arithmetic Mean(3.33)
Geometric Mean2.60
Coefficient Of Variation(53.93)
Mean Deviation1.60
Median(3.55)
Standard Deviation1.79
Sample Variance3.22
Range5.7368
R-Value(0.64)
Mean Square Error2.03
R-Squared0.41
Significance0.01
Slope(0.24)
Total Sum of Squares48.24

UroGen Net Income Per Share History

2025 -4.28
2024 -4.08
2023 -3.55
2022 -4.79
2021 -4.96
2020 -5.9
2019 -4.9

About UroGen Pharma Financial Statements

UroGen Pharma investors utilize fundamental indicators, such as Net Income Per Share, to predict how UroGen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss(4.08)(4.28)
When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock:
Check out the analysis of UroGen Pharma Correlation against competitors.
To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.02)
Revenue Per Share
2.389
Quarterly Revenue Growth
0.209
Return On Assets
(0.21)
Return On Equity
(14.81)
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.